Skip to NavigationSkip to content


AbbVie's Rinvoq hits target in psoriatic arthritis sub-population at Phase 3

AbbVie has unveiled new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq (upadacitinib) in the treatment of active psoriatic arthritis in adults who have responded inadequately or are intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).

The results revealed that 71% of patients receiving 15mg Rinvoq and 79% receiving 30mg achieved an ACR20 response after 12 weeks of treatment compared to 36% with placebo, meeting the trial’s primary endpoint.

New ICER report reveals most cost-effective rheumatoid arthritis therapies

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of three JAK inhibitors for treating rheumatoid arthritis (RA): AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib), and Eli Lilly’s Olumiant (baricitinib).

Head-to-head data revealed that Rinvoq demonstrated “statistically-significant but modestly higher rates of disease remission and improvement in other important outcomes” compared to AbbVie’s best-selling drug Humira; the report asserted that it could be assumed with “moderate certain

AbbVie's Rinvoq impresses at Phase 3 in active psoriatic arthritis sub-population

AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy met its primary endpoint in the treatment of  active psoriatic arthritis in adult patients who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs (bDMARDs).

The data revealed that both 15mg and 30mg formulations generated an ACR20 response on the American College of Rheumatology’s measure of the disease in 57% and 64% of patients respectively, following 12 weeks of treatment compared to 24% with placebo.

AbbVie scoops up FDA approval for Rinvoq in moderately to severely active rheumatoid arthritis

The FDA has awarded marketing authorisation to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis, it has emerged, in adult patients who have shown inadequate response or intolerance to methotrexate (MTX).

Data submitted in support of the application was drawn from one of the largest Phase 3 trial programmes in this indication, encompassing around 4,400 patients across five studies; Rinvoq met all primary and ranked secondary endpoints across these studies.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches